Search for: "Holman, Appeal of"
Results 81 - 100
of 213
Sorted by Relevance
|
Sort by Date
26 Aug 2023, 11:30 am
By Chris Holman Sun Pharmaceutical v. [read post]
13 Nov 2012, 1:34 am
Appeal allowed. [read post]
28 Oct 2011, 6:43 am
So how did David Holman, counsel for Mabon Limited, turn this into something dramatic? [read post]
15 Jun 2011, 1:07 pm
Judge Sudderth’s decision was appealed to the Second Court of Appeals, who, sitting en banc, upheld Judge Sudderth’s ruling. [read post]
10 Jun 2010, 3:58 am
(Holman's Biotech IP Blog)(Patent Docs) (Patent Docs) Cenestin (Conjugated estrogens) US: Teva’s patent for Cenestin under threat due to file wrapper estoppel (IP Factor) Cipro (Ciprofloxacin) – US: Court of Appeals for the Second Circuit invites examination of reverse settlement agreements by the Full Court of Appeals (IP Whiteboard) Combivir (Lamivudine, Zidovudine) – US: GlaxoSmithKline and Teva reach settlement in Combivir dispute (Patent Docs)… [read post]
24 Mar 2010, 4:45 am
(En Banc Decision) (Patently-O) (Patent Docs) (Holman's Biotech IP Blog) (Inventive Step) US: CAFC transfers ‘hot potato’ diagnostic method case: Laboratory Corp. of America Holdings v. [read post]
10 Aug 2010, 8:44 pm
Highlights this week included: CAFC: Genus-species; doctrine of equivalents; and patentable subject matter: Intervet v Merial Limited (Patently-O) (Holman’s Biotech IP Blog) (IP Spotlight) (IPBiz) (Patent Docs) Angiomax (Bivalirudin) – US: The Medicines Company prevails in patent term extension dispute; USPTO acts quickly to comply with court order (Patent Docs) (Patent Docs) (IPBiz) Skelaxin (Metaxalone) – US: CAFC: Ignoring non-patentable elements while judging… [read post]
10 Oct 2008, 11:32 am
You can separately subscribe to the Pharma & Biotech edition of the IP Thinktank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com] Highlights this week included: Mircera (Methoxy polyethylene glycol-epoetin beta) - US: Trial judge grants permanent injunction in case relating to recombinant erythropoietin (EPO) patent: Amgen v… [read post]
5 Apr 2010, 8:46 am
Kim Vanpelt and Anthony Lee Stanley remain on death row at Holman Prison in Atmore. [read post]
13 Apr 2017, 5:00 am
But in a recent decision, a the three-judge panel rejected Work’s appeal against Holman’s ruling. [read post]
23 Feb 2023, 2:56 pm
by Chris Holman C.R. [read post]
21 Apr 2023, 9:27 am
By Chris Holman Amgen Inc. v. [read post]
29 Jul 2008, 10:42 pm
G appealed. [read post]
12 Feb 2023, 9:01 pm
Ivey hoped to appeal to her better angels. [read post]
27 Jul 2012, 8:21 am
The application was heard by Mr Justice Holman, who found:1. [read post]
12 Oct 2011, 3:46 am
General Australian Senate Committee issues recommendation on Gene Patenting Bill (Patent Docs) EU: Paediatrics and transitional periods: a reader writes (The SPC Blog) Indian generics Aurobindo Pharma Limited and MedChem join Medicines Patent Pool (Spicy IP) (IP Watch) (IPBiz) Italy: Generics can be sued in the courts of the pharmacies, says the Court of Turin (Kluwer Patent Blog) US: Appealing premarket disputes in the Device Center: Reform is needed (FDA Law Blog) US: Lawyer,… [read post]
13 May 2011, 11:20 pm
(Holman’s Biotech IP Blog) (Patent Docs) (Patently-O) General / ?? [read post]
23 Feb 2011, 3:35 am
(Patentology) China: Patentability of dosage regime invention in the form of Swiss-type claim under Chinese patent law (jiplp) US: Legislation to ban authorized generics during 180-day exclusivity period makes a comeback in Congress (FDA Law Blog) US: Market exclusivity, data exclusivity and S. 3921 (Holman’s Biotech IP Blog) US: President’s budget proposal increases funding for basic research but seeks to ‘trim’ data exclusivity period and pay-for-delay agreements… [read post]
5 Mar 2008, 11:17 am
The incumbent for Place 2 is Republican Dixon Holman, who has been forced to retire by Texas’s retirement age for judges. [read post]
18 Feb 2010, 7:39 am
” For the study, I analyzed 2858 Board of Patent Appeals and Interference (BPAI) patent opinions decided January-June 2009. [read post]
